PMID- 36686714
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230202
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Efficacy and safety of weekly versus triweekly cisplatin treatment concomitant 
      with radiotherapy for locally advanced nasopharyngeal carcinoma: A systematic 
      review and pooled analysis.
PG  - 999027
LID - 10.3389/fphar.2022.999027 [doi]
LID - 999027
AB  - Background: Most nasopharyngeal carcinoma cases are diagnosed at an advanced 
      stage due to their hidden anatomical structure and atypical clinical symptoms and 
      often require chemoradiotherapy. Here, we present a systematic review and pooled 
      analysis to synthesize existing research on the efficacy and adverse effects of 
      weekly versus triweekly cisplatin chemotherapy concomitant with radiotherapy for 
      locally advanced nasopharyngeal carcinoma (LANPC). Methods: We searched the 
      PubMed, Embase, and Cochrane Library databases from inception to 1 September 
      2021, for relevant original research articles published in English. The 
      literature search and data extraction were done independently by two 
      investigators. We used random-effects models to provide point estimates [95% 
      confidence interval (CI)] of overall response rate (ORR), overall survival (OS), 
      progression-free survival (PFS), locoregional recurrence-free survival (LRFS), 
      distant metastasis-free survival (DMFS) and the incidence rate of adverse effects 
      (AEs) and with subgroup analysis according to each study type. The primary 
      endpoints were ORR, OS, and PFS; LRFS, DMFS, and grade >/=3 acute AEs were 
      secondary endpoints. Results: In total, 2,305 patients of eight studies were 
      included in this review. We found that patients who were administered cisplatin 
      weekly or triweekly had no differences in ORR, OS, PFS, DMFS, LRFS, severe 
      mucositis, dermatitis, nausea/vomiting or nephrotoxicity. Patients who were 
      administered weekly cisplatin were at a higher risk of hematological toxicity 
      compared with patients who received the chemotherapy triweekly. Conclusion: Our 
      findings suggest that both regimens could be recommended as the standard of care 
      for the chemoradiotherapy treatment of LANPC, the perceived benefit of lower 
      toxicity with weekly cisplatin could not be established.
CI  - Copyright (c) 2023 Tian, Zhu and Zhang.
FAU - Tian, Xin
AU  - Tian X
AD  - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 
      China.
FAU - Zhu, Qiuxia
AU  - Zhu Q
AD  - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 
      China.
FAU - Zhang, Zhenyong
AU  - Zhang Z
AD  - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 
      China.
LA  - eng
PT  - Systematic Review
DEP - 20230105
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9849582
OTO - NOTNLM
OT  - cisplatin
OT  - nasopharyngeal carcinoma
OT  - radiotherapy
OT  - triweekly
OT  - weekly
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/24 06:00
MHDA- 2023/01/24 06:01
PMCR- 2023/01/05
CRDT- 2023/01/23 04:54
PHST- 2022/07/20 00:00 [received]
PHST- 2022/12/19 00:00 [accepted]
PHST- 2023/01/23 04:54 [entrez]
PHST- 2023/01/24 06:00 [pubmed]
PHST- 2023/01/24 06:01 [medline]
PHST- 2023/01/05 00:00 [pmc-release]
AID - 999027 [pii]
AID - 10.3389/fphar.2022.999027 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Jan 5;13:999027. doi: 10.3389/fphar.2022.999027. 
      eCollection 2022.